Anna Kramvis、Kyong-Mi Chang、Maura Dandri、Patrizia Farci、Dieter Glebe、胡建明、Harry L. A. Janssen、Daryl T. Y. Lau、Capucine Penicaud、Teresa Pollicino、Barbara Testoni、Florian Van Bömmel、Ourania Andrisani、Maria Beumont-Mauviel、Timothy M. Block、Henry L. Y. Chan、Gavin A. Cloherty、William E. Delaney、Anna Maria Geretti、Adam Gehring、Kathy Jackson、Oliver Lenz、Mala K. Maini、Veronica Miller、Ulrike Protzer、Jenny C. Yang、Man-Fung Yuen、Fabien Zoulim 和 Peter A. Reville
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook
Anna Kramvis, Kyong-Mi Chang, Maura Dandri, Patrizia Farci, Dieter Glebe, Jianming Hu, Harry L. A. Janssen, Daryl T. Y. Lau, Capucine Penicaud, Teresa Pollicino, Barbara Testoni, Florian Van Bömmel, Ourania Andrisani, Maria Beumont-Mauviel, Timothy M. Block, Henry L. Y. Chan, Gavin A. Cloherty, William E. Delaney, Anna Maria Geretti, Adam Gehring, Kathy Jackson, Oliver Lenz, Mala K. Maini, Veronica Miller, Ulrike Protzer, Jenny C. Yang, Man-Fung Yuen, Fabien Zoulim & Peter A. Revill
Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. Various stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed, and knowledge gaps in understanding and interpretation of HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses, opportunities and challenges of HBV biomarkers.
Key points
As new therapies for hepatitis B virus (HBV) infection become available, new biomarkers to monitor viral and host responses are urgently needed.
This Roadmap summarizes current knowledge on existing and emerging serum biomarkers in the context of chronic HBV infection.
This Roadmap discusses the strengths, weaknesses, opportunities and challenges of serum HBV biomarkers.
This Roadmap provides suggestions of the way forward to advance the biomarkers required to fast-track an HBV cure for all, irrespective of resources, HBV genotype or disease stage.